NASDAQ
16.97USD
+0.05 (+0.30%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
879.5M
P/E
—
EPS
—
Beta
0.17
52W range
13.08-21.03
Day range
16.92–16.99
Open
16.93
Prev close
16.92
Volume
404.1K
Avg volume
556K
Dividend
0.00
IPO
2014-05-16
https://www.businesswire.com/news/home/20260815466380/en/TBPH-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-Theravance-Biopharma-Inc.-is-Obtaining-a-Fair-Price-for-its-Shareholders/ · 8/15/2026-0.30
https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-element-solutions-is-obtaining-a-fair-price-for-public-shareholders-302818603.html · 7/6/2026-0.60
https://www.zacks.com/stock/news/2945126/theravance-stock-down-3-after-zymeworks-announces-buyout?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2945126 · 6/30/2026-0.40
https://www.zacks.com/stock/news/2942613/silence-therapeutics-sln-surges-26-0-is-this-an-indication-of-further-gains?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2942613 · 6/25/2026+0.10
https://www.zacks.com/stock/news/2880017/down-30-6-in-4-weeks-here-s-why-you-should-you-buy-the-dip-in-theravance-bio-tbph?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|rsi-2880017 · 3/6/2026+0.70
https://www.zacks.com/stock/news/2878770/tbph-stock-plunges-26-on-failure-of-late-stage-msa-study?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2878770 · 3/4/2026-1.00
https://www.zacks.com/stock/news/2788901/theravance-biopharma-tbph-q3-earnings-and-revenues-beat-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2788901 · 11/11/2025+0.80
https://www.benzinga.com/trading-ideas/movers/25/10/48324539/paccar-posts-downbeat-earnings-joins-neuphoria-therapeutics-citius-pharmaceuticals-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session · 10/21/2025-0.50
https://www.zacks.com/stock/news/2750217/theravance-bio-tbph-up-9-8-since-last-earnings-report-can-it-continue?cid=CS-STOCKNEWSAPI-FT-realtime_blog-2750217 · 9/11/2025+0.60
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
